CARDIFF ONCOLOGY INC.
Company Snapshot
Company Overview
TrovaGene Inc. develops and commercializes urine-based (i.e., transrenal) molecular diagnostic products. TrovaGene’s approach is based on the discovery that cell-free fragments of DNA (resulting from normal cell death) circulating in the blood can cross the kidney barrier and end up in the urine. TrovaGene’s platforms for detecting this DNA include digital PCR for isolating and amplifying DNA fragments and NGS for sequencing the DNA fragments.
TrovaGene targets oncology applications, particularly mutations in KRAS, BRAF and PIK3CA oncogenes. The company believes that these three oncogenes cover 15% of U.S. cancer patients.
Trovagene launched NGS-based tests to detecting BRAF, V600E and KRAS. The company is developing a test for EGFR T790M.
Trovagene’s tests are performed at its CLIA-certified laboratory in San Diego, Calif. and run on the Illumina MiSeq platform.
A key feature of Trovagene’s technology is its ability to analyze circulating DNA from a range of body fluids: plasma, serum and urine.
In particular, urine is a good sample format because it can be obtained in large quantities, can be tested at high frequency and the patient does not need to travel to a laboratory. Trovagene’s focus on urine differentiates it from other companies in the liquid biopsy industry.
Trovagene uses an NGS platform for its assays, having migrated away from droplet digital PCR. The company has unique DNA enrichment methods that are optimized for small DNA fragments, allowing analysis of urine samples.
In January 2017, Trovagene extended its geographic distribution for liquid biopsy tests into Europe and the Middle East. This included signing on new distribution partners in the Middle East, Africa and Central and South Asia (Alliance Global), Italy (Instituto Diagnostico and Sorgente Genetics Varelli), Israel (Progenetics), France, Belgium and Switzerland (Amplitech), Bulgaria and Eastern Europe (NM Genomix) and Spain and Portugal (Diagnostica Longwood). These alliances greatly strengthened Trovagene’s geographic business for liquid biopsy kits and systems.
In March 2017, Trovagene began emphasizing its precision cancer therapeutics business by completing company restructuring. Trovagene will still maintain a laboratory for clinical services to pharmaceutical companies and for internal use.
As a result of this restructuring, Trovagene is focused on the development of oncology drugs that target mitosis. The company has several candidates in clinical trial. For liquid biopsy, Trovagene is using biomarkers to assess how well a patient is responding to drug treatment.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
CARDIFF ONCOLOGY INC. In News
Company's Business Segments
- Product : Onvansertib
- Service : Clinical Research, Genomic Integration, Others
Applications/End User Industries
- Healthcare
- Pharmaceuticals
- Biotechnology
- Research Institutions